Immunovant IMVT
NASDAQ IMVT
$33.62 -0.03 (-0.09%)
At close: Oct 2, 2026 · 4:00 PM EDT

Immunovant (IMVT) Change in Accured Expenses (2019 - 2026)

Updated

Immunovant (IMVT) reported Change in Accured Expenses of $10.08 million for fiscal Q1 2027 (quarter ended Jun 30, 2026), compared with -$5.3 million a year earlier and down 74.3% from the prior quarter.

Analysis

Immunovant (IMVT) Change in Accured Expenses (2019 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Immunovant's Change in Accured Expenses came in at $60.39 million, up 437.9% year-over-year; for FY2026 (ended Mar 31, 2026), it came in at $45 million, up 404.3% from FY2025.

  • Change in Accured Expenses has a five-year compound annual growth rate of 58.7% (FY2021 to FY2026).
  • By fiscal year, Change in Accured Expenses came in at $8.92 million in FY2025 (+561.5%), $1.35 million in FY2024 (-91.3%), $15.57 million in FY2023 (+64.4%) and $9.47 million in FY2022 (+112.0%).
  • Five-year quarterly Change in Accured Expenses spans a low of -$17.29 million in fiscal Q1 2024 and a high of $39.29 million in fiscal Q4 2026.
  • Year over year, Change in Accured Expenses gained in 1 of the last four quarters, with an average decline of 37.3%.
  • The high point for year-over-year Change in Accured Expenses in five years was fiscal Q2 2024 (growth of 103.8%); the low point was fiscal Q4 2025 (a decline of 88.6%).
  • Per Business Quant data, the three fiscal quarters before Q1 2027 came in at $39.29 million (Q4 2026), $756,000 (Q3 2026) and $10.26 million (Q2 2026).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Accured Exp. (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn -
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 2.96 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 1.20 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn -251.00 Mn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn -
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 901.00 Mn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn 338.00 Mn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn -
10 Immunovant 6.93 Bn 6.93 Bn - 10.08 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 10.08 Mn
Mar 31, 2026 39.29 Mn
Dec 31, 2025 756,000.00
Sep 30, 2025 10.26 Mn
Jun 30, 2025 -5.30 Mn
Mar 31, 2025 1.76 Mn
Dec 31, 2024 4.12 Mn
Sep 30, 2024 10.65 Mn
Jun 30, 2024 -7.61 Mn
Mar 31, 2024 15.46 Mn
Dec 31, 2023 -5.34 Mn
Sep 30, 2023 8.53 Mn
Jun 30, 2023 -17.29 Mn
Mar 31, 2023 14.29 Mn
Dec 31, 2022 2.64 Mn
Sep 30, 2022 4.19 Mn
Jun 30, 2022 -5.54 Mn
Mar 31, 2022 -6.72 Mn
Dec 31, 2021 8.29 Mn
Sep 30, 2021 6.73 Mn
API Access

Immunovant Change in Accured Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=change-in-accured-expenses&ticker=IMVT&period=max&api_key=YOUR_API_KEY